Balcinrenone vs HRS-1780

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: Mineralocorticoid receptor · full Chronic Kidney Disease pipeline

Balcinrenone

Developed by AstraZeneca

Phase 3 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT04595370 · Phase 2 · completed

The trial was randomized and quadruple-blind, with dapagliflozin as the active comparator, but the primary endpoint was the surrogate biomarker UACR rather than a clinical heart-failure or kidney outcome. The primary comparison was not statistically significant, and the study had relatively small analyzed groups after placebo and AZD9977 monotherapy arms were removed early.

Next expected readout: July 2030 · NCT07624305 (registry estimate)

Reported efficacy

Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 (Baseline (Day 1) to Week 12): Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 (Baseline (Day 1) to Week 12): AZD9977 15 mg + Dapagliflozin 10 mg -56.391% (95% CI -71.528--33.207) vs AZD9977 50 mg + Dapagliflozin 10 mg -42.085% (95% CI -64.174--6.376) vs AZD9977 150 mg + Dapagliflozin 10 mg -58.047% (95% CI -73.560--33.430) vs AZD9977 150 mg -45.01% (95% CI NA-NA) vs Dapagliflozin 10 mg -34.318% (95% CI -58.204-3.220) vs Placebo 230.32% (95% CI NA-NA); p=0.3645 (AZD9977 15 mg + Dapagliflozin 10 mg vs AZD9977 50 mg + Dapagliflozin 10 mg vs AZD9977 150 mg + Dapagliflozin 10 mg vs Dapagliflozin 10 mg) (missed)

Result source: NCT04595370

HRS-1780

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Chronic Kidney Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2030 · NCT07419828 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBalcinrenoneHRS-1780
Kidney composite outcome—Trial running · NCT07624305—Trial running · NCT07419828
UACR, % change-58.0% vs 230.3%−288.4 vs placebo150 mg + 10 mg · wk 12 · n 25NCT04595370
7 other results
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · primary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · primary NCT04595370
  • -45.0% vs 230.3% 150 mg · wk 12 · n 5 · Phase 2 · primary NCT04595370
  • -58.0% vs 230.3% 150 mg + 10 mg · wk 12 · n 25 · Phase 2 · secondary NCT04595370
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · secondary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · secondary NCT04595370
  • -45.0% vs 230.3% 150 mg · wk 12 · n 5 · Phase 2 · secondary NCT04595370
—Trial running · NCT07419828
eGFR slope—Trial running · NCT07624305—Trial running · NCT07419828
Haemoglobin, change—Trial running · NCT07624305—Trial running · NCT07419828

Kidney composite outcome

Balcinrenone
—Trial running · NCT07624305
HRS-1780
—Trial running · NCT07419828

UACR, % change

Balcinrenone
-58.0% vs 230.3%−288.4 vs placebo150 mg + 10 mg · wk 12 · n 25NCT04595370
7 other results
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · primary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · primary NCT04595370
  • -45.0% vs 230.3% 150 mg · wk 12 · n 5 · Phase 2 · primary NCT04595370
  • -58.0% vs 230.3% 150 mg + 10 mg · wk 12 · n 25 · Phase 2 · secondary NCT04595370
  • -42.1% vs 230.3% 50 mg + 10 mg · wk 12 · n 23 · Phase 2 · secondary NCT04595370
  • -56.4% vs 230.3% 15 mg + 10 mg · wk 12 · n 32 · Phase 2 · secondary NCT04595370
  • -45.0% vs 230.3% 150 mg · wk 12 · n 5 · Phase 2 · secondary NCT04595370
HRS-1780
—Trial running · NCT07419828

eGFR slope

Balcinrenone
—Trial running · NCT07624305
HRS-1780
—Trial running · NCT07419828

Haemoglobin, change

Balcinrenone
—Trial running · NCT07624305
HRS-1780
—Trial running · NCT07419828
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HRS-1780: no structured comparison results are available for Chronic Kidney Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Balcinrenone: 4 of 4 rows · HRS-1780: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBalcinrenone
Dropout rate
14.3%150 mga
NCT04595370 · Phase 2
show 3 more results
25%150 mg + 10 mg
NCT04595370 · Phase 2 · combination
24.2%50 mg + 10 mg
NCT04595370 · Phase 2 · combination
5.7%15 mg + 10 mg
NCT04595370 · Phase 2 · combination
Discontinued due to AEs
14.3%150 mga
NCT04595370 · Phase 2
show 3 more results
8.3%150 mg + 10 mg
NCT04595370 · Phase 2 · combination
12.1%50 mg + 10 mg
NCT04595370 · Phase 2 · combination
0%15 mg + 10 mg
NCT04595370 · Phase 2 · combination
Serious AEs
0%150 mga
NCT04595370 · Phase 2
show 3 more results
5.9%150 mg + 10 mg
NCT04595370 · Phase 2 · combination
9.7%50 mg + 10 mg
NCT04595370 · Phase 2 · combination
3%15 mg + 10 mg
NCT04595370 · Phase 2 · combination
Most frequent reported AEs
150 mga
chronic kidney disease 16.7% (placebo 0%)
gingival recession 16.7% (placebo 0%)
headache 16.7% (placebo 0%)
NCT04595370 · Phase 2
show 3 more results
150 mg + 10 mg
nasopharyngitis 8.8% (placebo 0%)
chronic kidney disease 5.9% (placebo 0%)
diarrhoea 5.9% (placebo 20%)
NCT04595370 · Phase 2 · combination
50 mg + 10 mg
urinary tract infection bacterial 6.5% (placebo 0%)
chronic kidney disease 3.2% (placebo 0%)
hyperkalaemia 3.2% (placebo 0%)
NCT04595370 · Phase 2 · combination
15 mg + 10 mg
chronic kidney disease 3% (placebo 0%)
colitis 0% (placebo 20%)
diabetes mellitus 0% (placebo 20%)
NCT04595370 · Phase 2 · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Balcinrenone

UACR -58.047% (n=25) vs 230.32% (n=3) placebo @ 12wk150 mg + 10 mg
percent change · % of baseline
NCT04595370 · Phase 2 · combination
show 7 more results
-45.01% (n=5) vs 230.32% (n=3) placebo @ 12wk150 mg
NCT04595370 · Phase 2
-58.047% (n=25) vs 230.32% (n=7) placebo @ 12wk150 mg + 10 mg
NCT04595370 · Phase 2 · combination
-45.01% (n=5) vs 230.32% (n=7) placebo @ 12wk150 mg
NCT04595370 · Phase 2
-42.085% (n=23) vs 230.32% (n=3) placebo @ 12wk50 mg + 10 mg
NCT04595370 · Phase 2 · combination
-42.085% (n=23) vs 230.32% (n=7) placebo @ 12wk50 mg + 10 mg
NCT04595370 · Phase 2 · combination
-56.391% (n=32) vs 230.32% (n=3) placebo @ 12wk15 mg + 10 mg
NCT04595370 · Phase 2 · combination
-56.391% (n=32) vs 230.32% (n=7) placebo @ 12wk15 mg + 10 mg
NCT04595370 · Phase 2 · combination
eGFR -5.307 vs 6.88 placebo mL @ 12wk150 mg + 10 mg
absolute change · mL
NCT04595370 · Phase 2 · combination
show 3 more results
-0.923 vs 6.88 placebo mL @ 12wk150 mg
NCT04595370 · Phase 2
-1.16 vs 6.88 placebo mL @ 12wk50 mg + 10 mg
NCT04595370 · Phase 2 · combination
-1.432 vs 6.88 placebo mL @ 12wk15 mg + 10 mg
NCT04595370 · Phase 2 · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Balcinrenone's landscape · HRS-1780's landscape